# Wealthfront Corp: financial statements, quarterly

WLTH · Nasdaq · CIK 1524566 · [Financials](/sectors/financials.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/wlth.md) · [Financials](/companies/wlth/financials.md) · [Filings](/companies/wlth/filings.md) · [Insiders](/companies/wlth/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wlth/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-10-31) | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [80.3](/filings/0001628280-26-003332.md) | [82.7 d](/filings/0001628280-26-027232.md) | [84.5](/filings/0001628280-26-042874.md) | [91.1](/filings/0001628280-26-061848.md) | [93.2](/filings/0001628280-26-003332.md) | [96.1 d](/filings/0001628280-26-027232.md) | [90.5](/filings/0001628280-26-042874.md) | [91.9](/filings/0001628280-26-061848.md) |
| Cost of revenue | $m | [8.0](/filings/0001628280-26-003332.md) | [8.5 d](/filings/0001628280-26-027232.md) | [8.7](/filings/0001628280-26-042874.md) | [9.6](/filings/0001628280-26-061848.md) | [10.2](/filings/0001628280-26-003332.md) | [9.6 d](/filings/0001628280-26-027232.md) | [10.0](/filings/0001628280-26-042874.md) | [10.8](/filings/0001628280-26-061848.md) |
| Research and development | $m | [17.1](/filings/0001628280-26-003332.md) | [18.1 d](/filings/0001628280-26-027232.md) | [20.2](/filings/0001628280-26-042874.md) | [21.2](/filings/0001628280-26-061848.md) | [20.9](/filings/0001628280-26-003332.md) | [150 d](/filings/0001628280-26-027232.md) | [33.7](/filings/0001628280-26-042874.md) | [34.0](/filings/0001628280-26-061848.md) |
| Interest expense | $m | [1.0](/filings/0001628280-26-003332.md) | [0.3 d](/filings/0001628280-26-027232.md) | [0.1](/filings/0001628280-26-042874.md) | [0.1](/filings/0001628280-26-061848.md) | [0.2](/filings/0001628280-26-003332.md) | [0.5 d](/filings/0001628280-26-027232.md) | [0.3](/filings/0001628280-26-042874.md) | [0.3](/filings/0001628280-26-061848.md) |
| Income tax | $m | [(0.5)](/filings/0001628280-26-003332.md) | [(0.6) d](/filings/0001628280-26-027232.md) | [8.2](/filings/0001628280-26-042874.md) | [5.1](/filings/0001628280-26-061848.md) | [3.8](/filings/0001628280-26-003332.md) | [(76.3) d](/filings/0001628280-26-027232.md) | [4.6](/filings/0001628280-26-042874.md) | [2.6](/filings/0001628280-26-061848.md) |
| Net income | $m | [30.0](/filings/0001628280-26-003332.md) | [32.1 d](/filings/0001628280-26-027232.md) | [25.9](/filings/0001628280-26-042874.md) | [34.7](/filings/0001628280-26-061848.md) | [30.9](/filings/0001628280-26-003332.md) | [(134) d](/filings/0001628280-26-027232.md) | [12.8](/filings/0001628280-26-042874.md) | [17.8](/filings/0001628280-26-061848.md) |
| Diluted EPS | $ per share | [0.22](/filings/0001628280-26-003332.md) | not reported | [0.18](/filings/0001628280-26-042874.md) | [0.24](/filings/0001628280-26-061848.md) | [0.21](/filings/0001628280-26-003332.md) | not reported | [0.07](/filings/0001628280-26-042874.md) | [0.10](/filings/0001628280-26-061848.md) |
| Basic EPS | $ per share | [0.77](/filings/0001628280-26-003332.md) | not reported | [0.64](/filings/0001628280-26-042874.md) | [0.86](/filings/0001628280-26-061848.md) | [0.72](/filings/0001628280-26-003332.md) | not reported | [0.08](/filings/0001628280-26-042874.md) | [0.12](/filings/0001628280-26-061848.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-01-31) | period not labelled (2024-01-31) | period not labelled (2024-07-31) | period not labelled (2024-10-31) | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [86.7](/filings/0001628280-26-027232.md) | not reported | [133](/filings/0001628280-26-003332.md) | [143](/filings/0001628280-26-027232.md) | [183](/filings/0001628280-26-042874.md) | [223](/filings/0001628280-26-061848.md) | [266](/filings/0001628280-26-003332.md) | [441](/filings/0001628280-26-061848.md) | [428](/filings/0001628280-26-042874.md) | [453](/filings/0001628280-26-061848.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [346](/filings/0001628280-26-027232.md) | not reported | not reported | [743](/filings/0001628280-26-003332.md) | [1,276](/filings/0001628280-26-061848.md) | [1,486](/filings/0001628280-26-042874.md) | [1,652](/filings/0001628280-26-061848.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [435](/filings/0001628280-26-027232.md) | not reported | not reported | [811](/filings/0001628280-26-003332.md) | [1,416](/filings/0001628280-26-061848.md) | [1,620](/filings/0001628280-26-042874.md) | [1,783](/filings/0001628280-26-061848.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [173](/filings/0001628280-26-027232.md) | not reported | not reported | [441](/filings/0001628280-26-003332.md) | [793](/filings/0001628280-26-061848.md) | [999](/filings/0001628280-26-042874.md) | [1,157](/filings/0001628280-26-061848.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [193](/filings/0001628280-26-027232.md) | not reported | not reported | [458](/filings/0001628280-26-003332.md) | [801](/filings/0001628280-26-061848.md) | [1,006](/filings/0001628280-26-042874.md) | [1,163](/filings/0001628280-26-061848.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.2](/filings/0001628280-26-061848.md) | not reported | [5.1](/filings/0001628280-26-061848.md) |
| Shareholders' equity | $m | [(273)](/filings/0001628280-26-027232.md) | [(181)](/filings/0001628280-26-027232.md) | [(42.5)](/filings/0001628280-26-003332.md) | [(30.9)](/filings/0001628280-26-003332.md) | [15.3](/filings/0001628280-26-061848.md) | [43.3](/filings/0001628280-26-061848.md) | [84.4](/filings/0001628280-26-061848.md) | [125](/filings/0001628280-26-003332.md) | [615](/filings/0001628280-26-061848.md) | [614](/filings/0001628280-26-061848.md) | [620](/filings/0001628280-26-061848.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-01-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [19.9 d](/filings/0001628280-26-027232.md) | [38.5](/filings/0001628280-26-042874.md) | [38.9 d](/filings/0001628280-26-061848.md) | [41.5 d](/filings/0001628280-26-003332.md) | [33.3 d](/filings/0001628280-26-027232.md) | [22.7](/filings/0001628280-26-042874.md) | [47.3 d](/filings/0001628280-26-061848.md) |
| Share repurchases | $m | [13.6 d](/filings/0001628280-26-027232.md) | [0.2](/filings/0001628280-26-042874.md) | [0.0 d](/filings/0001628280-26-061848.md) | [0.0 d](/filings/0001628280-26-003332.md) | [0.2 d](/filings/0001628280-26-027232.md) | [28.3](/filings/0001628280-26-042874.md) | [31.8 d](/filings/0001628280-26-061848.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2024-10-31) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [138](/filings/0001628280-26-003332.md) | [142](/filings/0001628280-26-042874.md) | [142](/filings/0001628280-26-061848.md) | [143](/filings/0001628280-26-003332.md) | [176](/filings/0001628280-26-042874.md) | [174](/filings/0001628280-26-061848.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 156,176,440 at 2026-09-14, from the cover of the [10-Q filed 2026-09-14](/filings/0001628280-26-061848.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.